{"id":8878,"date":"2004-11-06T03:09:00","date_gmt":"2004-11-06T03:09:00","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=8878"},"modified":"2013-11-05T11:58:06","modified_gmt":"2013-11-05T11:58:06","slug":"bms-submits-marketing-applications-for-entecavir-to-treat-hbv-in-us-and-europe","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/8878","title":{"rendered":"BMS submits marketing applications for entecavir to treat HBV in US and Europe"},"content":{"rendered":"<p><strong>Bristol-Myers Squibb Company has announced the submission of a New Drug Application to the US Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B. <\/strong><\/p>\n<p>The company also submitted a marketing authorisation application for entecavir to the European Medicines Evaluation Agency.<\/p>\n<p>Entecavir is an investigational oral antiviral discovered at Bristol-Myers Squibb that is designed to selectively inhibit the Hepatitis B virus, blocking all three steps in the replication process.<\/p>\n<p>Source: BMS press release<\/p>\n<p><a href=\"http:\/\/www.bms.com\/news\/press\/data\/fg_press_release_5036.html\">http:\/\/www.bms.com\/news\/press\/data\/fg_press_release_5036.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bristol-Myers Squibb Company has announced the submission of a New Drug Application to the US Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B. The company also submitted a marketing &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-8878","post","type-post","status-publish","format-standard","hentry","category-hepatitis-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/8878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=8878"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/8878\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=8878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=8878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=8878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}